Company Snapshot: KemPharm, Inc.

KMPH
Last	Change	Volume	High	Low

Company Overview

KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. Its product candidate includes KP415 and KP484 for the treatment of attention deficit hyperactivity disorder; and KP879 for the treatment of stimulant use disorder. The company also provides APADAZ, an immediate-release combination product candidate of benzhydrocodone and acetaminophen to treat the short-term management of acute pain. It has a collaboration agreement with KVK-Tech, Inc. to manufacture and commercialize APADAZ. The company was founded in 2006 and is headquartered in Celebration, Florida.

Client News

1. Oct 27 2021 AZSTARYS®, An Innovative ADHD Treatment Developed by KemPharm, to be Featured in a Poster Presentation at the 2021 Psych Congress
2. Oct 20 2021 KemPharm Announces Research Involving AZSTARYS® and Serdexmethylphenidate to be Featured in Poster Presentations at Multiple Medical Conferences during ADHD Awareness Month (October)
3. Oct 19 2021 KemPharm, Inc. Announces Uplisting to The Nasdaq Global Select Market
4. Sep 27 2021 KemPharm to Present at the Benzinga Healthcare Small Cap Conference